KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Change in Cash (2016 - 2025)

NovoCure's Change in Cash history spans 12 years, with the latest figure at -$241.2 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 944.14% year-over-year to -$241.2 million; the TTM value through Dec 2025 reached -$62.7 million, up 18.0%, while the annual FY2025 figure was -$62.7 million, 18.0% up from the prior year.
  • Change in Cash for Q4 2025 was -$241.2 million at NovoCure, down from $192.5 million in the prior quarter.
  • Across five years, Change in Cash topped out at $330.1 million in Q3 2021 and bottomed at -$481.1 million in Q4 2021.
  • The 5-year median for Change in Cash is $9.9 million (2023), against an average of -$7.1 million.
  • The largest YoY upside for Change in Cash was 2326.39% in 2021 against a maximum downside of 4557.77% in 2021.
  • A 5-year view of Change in Cash shows it stood at -$481.1 million in 2021, then skyrocketed by 73.35% to -$128.2 million in 2022, then skyrocketed by 167.12% to $86.1 million in 2023, then crashed by 126.85% to -$23.1 million in 2024, then plummeted by 944.14% to -$241.2 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Change in Cash are -$241.2 million (Q4 2025), $192.5 million (Q3 2025), and $22.7 million (Q2 2025).